International Review of Ophthalmology ›› 2025, Vol. 49 ›› Issue (1): 25-31.doi: 10.3760/cma.j.cn115500-20240722-01005

Previous Articles     Next Articles

Pathogenesis and potential drug  of cataract

Ma Lin1, Huang Lintao2, Shi Hang3, Wang Wanhe2, Wu Li'an3   

  1. 1 Graduate office of Xi'an Medical College, Xi'an Shaanxi 710068, China; 2Northwestern Polytechnical University, Xi'an Shaanxi 710072, China; 3 Xi'an People's Hospital (fourth hospital in Xi'an) Shaanxi Ophthalmology Hospital Northwest University Affiliated People's Hospital, Xi'an Shaanxi 710004, China
  • Received:2024-07-22 Online:2025-02-22 Published:2025-02-20
  • Contact: Wu Li'an, Email: wla105@126. com
  • Supported by:
    Key Research and Development Program of Shaanxi (2024SF-YBXM-323, 2024SF-YBXM-335); Key Research and Development Program of Shaanxi (2024SF-YBXM-335); Xi'an Municipal Health Commission Project (2023yb13); Xi'an Municipal Health Commission Project (2025zh02); Xi'an Science and Technology Planning Project (22YXYJ0059, 21YXYJ0047); Research Incubation Fund of Xi’an People’s Hospital (Xi’an Fourth Hospital) (2022LBSH05); Xi'an Fourth Hospital Research Incubation Fund Project (LH-10, FZ-72)

Abstract: The pathogenesis of cataracts is linked to multiple factors, with oxidative stress, excessive quinone substances, aldose reductase activity, and lens protein aggregation being the main mechanisms. Recently, many drugs and compounds have been identified through basic and animal studies as having potential anti-cataract effects. These include polyphenolic compounds extracted from plants, Ginkgo biloba leaves, ginger, and drugs like pirenoxine eye drops for excessive quinone substances. Aldose reductase inhibitors such as diosgenin and L-lysine and anti-lens protein aggregation agents like lanosterol and 25-hydroxycholesterol also show promise, indicating a shift towards molecular approaches in anti-cataract therapy. Despite the therapeutic potential seen in research, limitations such as the extrapolation of animal study results and individual variability currently hinder their clinical application. With further research, these drugs may be used in clinical settings in the future. (Int Rev Ophthalmol, 2025, 49:  25-31)

Key words: ataract, pathogenic mechanism, drug prevention and treatment